Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Cabozantinib + Pembrolizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cabozantinib | Cometriq | Cabometyx|Cabozantinib-s-malate|XL184 | AXL Inhibitor 29 FLT3 Inhibitor 64 KIT Inhibitor 57 MET Inhibitor 58 RET Inhibitor 52 ROS1 Inhibitor 20 VEGFR2 Inhibitor 37 | Cometriq (Cabometyx, cabozantinib) inhibits several receptor tyrosine kinases, including VEGFR2, FLT3, AXL, MET, RET, ROS1 fusions, and c-KIT (PMID: 27370605, PMID: 21926191). Cometriq (cabozantinib) is FDA approved for use in patients with medullary thyroid cancer, Cabometyx (cabozantinib) is FDA approved for use in patients with advanced renal cell carcinoma, hepatocellular carcinoma previously treated with sorafenib, adult and pediatric patients 12 years and older with locally advanced or metastatic differentiated thyroid cancer, and in combination with Opdivo (nivolumab) in patients with advanced renal cell carcinoma (FDA.gov). |
Pembrolizumab | Keytruda | MK-3475 | Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 112 | Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous squamous cell carcinoma, MSI-H or dMMR or TMB high advanced solid tumors, NSCLC and CD274 (PD-L1)-expressing NSCLC, squamous esophageal carcinoma, cervical cancer, and TNBC, in combination with platnum-based chemotherapy in NSCLC, with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, with axitinib or lenvatinib in RCC, with Lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, in combination with platinum and fluoropyrimidine-based chemotherapy for patients with esophageal or gastroesophageal carcinoma, in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemotherapy for CD274 (PD-L1)-positive, HER2-positive gastric or GFJ adenocarcinoma, in combination with fluoropyrimidine- and platinum-containing chemotherapy for HER2-negative gastric or GEJ adenocarcinoma, in combination with platinum-based chemotherapy, with or without bevacizumab, for patients with CD274 (PD-L1)-expressing (CPS>=1) cervical cancer, and in combination with gemcitabine and cisplatin for biliary tract cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04164979 | Phase II | Cabozantinib + Pembrolizumab | Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT05613413 | Phase II | Cabozantinib + Pembrolizumab | A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC) (LUNG-IST-127) | Recruiting | USA | 0 |
NCT04442581 | Phase II | Cabozantinib + Pembrolizumab | Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | Terminated | USA | 0 |
NCT03149822 | Phase Ib/II | Cabozantinib + Pembrolizumab | Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT04230954 | Phase II | Cabozantinib + Pembrolizumab | Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer | Terminated | USA | 0 |
NCT05052723 | Phase II | Cabozantinib + Pembrolizumab | Cabozantinib and Pembrolizumab in Metastatic Pancreas | Recruiting | USA | 0 |
NCT03534804 | Phase II | Cabozantinib + Pembrolizumab | Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab) | Active, not recruiting | USA | 0 |
NCT05182164 | Phase II | Cabozantinib + Pembrolizumab | Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas (PEMBROCABOSARC) | Recruiting | FRA | 0 |
NCT03468218 | Phase II | Cabozantinib + Pembrolizumab | Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Who Have Failed Platinum Based Therapy | Active, not recruiting | USA | 0 |
NCT03957551 | Phase Ib/II | Cabozantinib + Pembrolizumab | Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma | Recruiting | USA | 0 |